Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.

Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma. Gemcitabine is an analogue of pyrimidine cytosine and functions as an anti-metabolite. Structurally, however, gemcitabine has similarities to 5-aza-2-deoxycytidine (decitabine/Dacogen®), a DNA methyltransferase inhibitor (DNMTi). NSCLC, mesothelioma and prostate cancer cell lines were treated with decitabine and gemcitabine. Reactivation of epigenetically silenced genes was examined by RT-PCR/qPCR. DNA methyltransferase activity in nuclear extracts and recombinant proteins was measured using a DNA methyl-transferase assay, and alterations in DNA methylation status were examined using methylation-specific PCR (MS-PCR) and pyrosequencing. We observe a reactivation of several epigenetically silenced genes including GSTP1, IGFBP3 and RASSF1A. Gemcitabine functionally inhibited DNA methyltransferase activity in both nuclear extracts and recombinant proteins. Gemcitabine dramatically destabilised DNMT1 protein. However, DNA CpG methylation was for the most part unaffected by gemcitabine. In conclusion, gemcitabine both inhibits and destabilises DNA methyltransferases and reactivates epigenetically silenced genes having activity equivalent to decitabine at concentrations significantly lower than those achieved in the treatment of patients with solid tumours. This property may contribute to the anticancer activity of gemcitabine.

[1]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[2]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[3]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[4]  R. Stahel,et al.  First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. , 2011, Lung cancer.

[5]  T. Liloglou,et al.  UHRF1‐mediated tumor suppressor gene inactivation in nonsmall cell lung cancer , 2011, Cancer.

[6]  K. O'Byrne,et al.  The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer , 2011, Cancers.

[7]  John K Field,et al.  Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer. , 2011, Cancer letters.

[8]  Christof Niehrs,et al.  Gemcitabine Functions Epigenetically by Inhibiting Repair Mediated DNA Demethylation , 2010, PloS one.

[9]  R. Singal,et al.  Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. , 2010, Anticancer research.

[10]  J. Pollack,et al.  Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. , 2010, Cancer research.

[11]  V. Levenson,et al.  DNA methylation as a universal biomarker , 2010, Expert review of molecular diagnostics.

[12]  O. Hermanson,et al.  Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide , 2010, Oncogene.

[13]  Peter M. Ellis,et al.  First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  K. O'Byrne,et al.  Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. , 2009, European journal of cancer.

[15]  C. Unger,et al.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model , 2009, Clinical & Experimental Metastasis.

[16]  H. Kindler,et al.  Malignant pleural mesothelioma: an update on biomarkers and treatment. , 2009, Chest.

[17]  C. Unger,et al.  Liposomal gemcitabine (GemLip)—efficient drug against hormone‐refractory Du145 and PC‐3 prostate cancer xenografts , 2009, The Prostate.

[18]  A. D. De Marzo,et al.  Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.

[19]  Qingyuan Zhang,et al.  AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. , 2009, Biochemical and biophysical research communications.

[20]  K. O'Byrne,et al.  Targeting histone deacetylases for the treatment of disease , 2008, Journal of cellular and molecular medicine.

[21]  A. Cassidy,et al.  Hypomethylation of retrotransposable elements correlates with genomic instability in non‐small cell lung cancer , 2009, International journal of cancer.

[22]  K. Tkaczuk.  Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. , 2009, Clinical therapeutics.

[23]  K. O'Byrne,et al.  Advances in the systemic therapy of malignant pleural mesothelioma , 2008, Nature Clinical Practice Oncology.

[24]  F. Blackhall,et al.  Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer , 2007, Expert opinion on pharmacotherapy.

[25]  B. Loftus,et al.  In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer , 2007, British Journal of Cancer.

[26]  A. Perry,et al.  Discovery of DNA Hypermethylation Using a DHPLC Screening Strategy , 2007, Epigenetics.

[27]  G. Peters,et al.  No evidence of gemcitabine accumulation during weekly administration , 2005, European Journal of Clinical Pharmacology.

[28]  K. Ghoshal,et al.  5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.

[29]  R. Pazdur,et al.  Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.

[30]  Amie Y Lee,et al.  Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. , 2005, Cancer research.

[31]  K. Robertson,et al.  Doxorubicin Inhibits DNMT1, Resulting in Conditional Apoptosis , 2004, Molecular Pharmacology.

[32]  Biao He,et al.  Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma , 2004, Oncogene.

[33]  遠藤 秀紀.  RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication , 2004 .

[34]  A. Protopopov,et al.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. , 2002, Cancer research.

[35]  Deidre Wild.  A step in the right direction. , 2002, Nursing older people.

[36]  J. Minna,et al.  Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. , 2001, Cancer research.

[37]  B. Robinson,et al.  New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production , 2000, Cancer Chemotherapy and Pharmacology.

[38]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[39]  M. Rudnicki,et al.  Simplified mammalian DNA isolation procedure. , 1991, Nucleic acids research.